Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.

Author: HanauerS B

Paper Details 
Original Abstract of the Article :
Sulfasalazine was the first aminosalicylate to be used for induction and maintenance therapy of ulcerative colitis (UC). Initial trials demonstrated a dose response that was compromised by dose-related intolerance. Recognition that the 5-aminosalicylic acid moiety (5-ASA, mesalazine) is the active i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/j.1365-2036.2006.03058.x

データ提供:米国国立医学図書館(NLM)

High-Dose Aminosalicylates for Ulcerative Colitis

The intricate world of inflammatory bowel diseases presents a myriad of challenges, and ulcerative colitis (UC) is a debilitating condition that affects the colon. This research explores the use of high-dose aminosalicylates, a class of medications used to treat UC, in inducing and maintaining remission. The authors provide a comprehensive review of the literature, highlighting the efficacy and safety of high-dose aminosalicylates in managing UC.

High-Dose Aminosalicylates: A Promising Approach for UC

The study reveals that increasing the dose of mesalazine, a specific aminosalicylate, can significantly improve the induction of remission in patients with UC, particularly those with more moderate disease activity. Furthermore, the authors emphasize that high-dose aminosalicylates are well-tolerated, with minimal dose-related side effects.

Managing UC with Confidence

This research offers valuable insights for patients with UC and their healthcare providers. By understanding the efficacy and safety profile of high-dose aminosalicylates, clinicians can tailor treatment plans to optimize patient outcomes and empower individuals to manage their condition with confidence and control.

Dr. Camel's Conclusion

This review sheds light on the potential of high-dose aminosalicylates in managing ulcerative colitis. The findings highlight their effectiveness in inducing and maintaining remission, providing patients with a valuable tool for managing this challenging condition. It's a reminder that we must continually explore new treatment options and refine our understanding of existing therapies to provide the best possible care for individuals living with inflammatory bowel diseases.

Date :
  1. Date Completed 2007-05-21
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

16961743

DOI: Digital Object Identifier

10.1111/j.1365-2036.2006.03058.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.